Natalie Nightingale
Natalie Nightingale has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
A. Marilise Marrache
Lundbeck Canada Inc., 2600 Alfred-Nobel boulevard, Suite 400, Saint-Laurent, QC H4S 0A9, Canada
1 shared publicationAli Tehrani
IQVIA Solutions Canada Inc
1 shared publication- Bishal Gyawali
Department of Oncology, Queen’s University , Kingston, ON
1 shared publication Calum S. Neish
Real World Solutions, IQVIA Solutions Canada Inc, 1875 Buckhorn Gate, Suite 402, Mississauga, ON L4W 5P1, Canada
1 shared publicationCarmen Fung
Manager of Data & Analytics Centre, Janssen Inc
1 shared publication- Ceryl Tan
Department of Molecular Genetics, University of Toronto
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0362402
Machine learning approaches for the identification of real-world predictors of mepolizumab response
Background: Mepolizumab improves control and reduces clinically significant exacerbations in severe asthma patients. Further research is needed to understand factors influencing patient response. Objective: Identify predictors of response to mepolizumab using machine learning techniques. Methods: Thirty clinically relevant features from the REALITI-A dataset were analyzed. Response to mepolizumab was defined as change in clinically significant exacerbations at Year 1 post-exposure, being free from clinically significant exacerbations at Year 1, and being free from clinically significant exacerbations at both Year 1 and Year 2 post-exposure for primary, secondary, and exploratory analyses, respectively. Linear/logistic regression, random forest, and XGBoost models were tested. The best-performing model based on R 2 or classification accuracy was used for feature selection. A SHapley Additive exPlanations post-hoc analysis was conducted. Results: The primary and secondary analyses included 685 patients; the exploratory analysis included 529 patients. Using XGBoost for the primary analysis, higher pre-exposure clinically significant exacerbations rate, lower body mass index, total immunoglobulin E, lower baseline activity impairment, and lower baseline Asthma Control Questionnaire-5 score were top predictors. For the secondary analysis, the random forest model identified lower pre-exposure clinically significant exacerbations rate, residency outside the United Kingdom, and lower baseline Asthma Control Questionnaire-5 score, body mass index, and baseline activity impairment as top predictors. For the exploratory analysis, XGBoost identified residency outside the United Kingdom, and lower pre-exposure clinically significant exacerbations rate, baseline Asthma Control Questionnaire-5 score, eosinophil levels, and body mass index as top predictors. Conclusion: Machine learning models identified key predictors of response to mepolizumab, which could guide clinical decision-making and improve patient outcomes in severe asthma patients.
- 13 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0362402
Open AccessMachine learning approaches for the identification of real-world predictors of mepolizumab response
Background: Mepolizumab improves control and reduces clinically significant exacerbations in severe asthma patients. Further research is needed to understand factors influencing patient response. Objective: Identify predictors of response to mepolizumab using machine learning techniques. Methods: Thirty clinically relevant features from the REALITI-A dataset were analyzed. Response to mepolizumab was defined as change in clinically significant exacerbations at Year 1 post-exposure, being free from clinically significant exacerbations at Year 1, and being free from clinically significant exacerbations at both Year 1 and Year 2 post-exposure for primary, secondary, and exploratory analyses, respectively. Linear/logistic regression, random forest, and XGBoost models were tested. The best-performing model based on R 2 or classification accuracy was used for feature selection. A SHapley Additive exPlanations post-hoc analysis was conducted. Results: The primary and secondary analyses included 685 patients; the exploratory analysis included 529 patients. Using XGBoost for the primary analysis, higher pre-exposure clinically significant exacerbations rate, lower body mass index, total immunoglobulin E, lower baseline activity impairment, and lower baseline Asthma Control Questionnaire-5 score were top predictors. For the secondary analysis, the random forest model identified lower pre-exposure clinically significant exacerbations rate, residency outside the United Kingdom, and lower baseline Asthma Control Questionnaire-5 score, body mass index, and baseline activity impairment as top predictors. For the exploratory analysis, XGBoost identified residency outside the United Kingdom, and lower pre-exposure clinically significant exacerbations rate, baseline Asthma Control Questionnaire-5 score, eosinophil levels, and body mass index as top predictors. Conclusion: Machine learning models identified key predictors of response to mepolizumab, which could guide clinical decision-making and improve patient outcomes in severe asthma patients.
- Open Access
- 18 April 2026
- Published by Elsevier in International Psychogeriatrics
- Vol. 38 (5) , 100209
Treatment patterns of agitation associated with Alzheimer’s dementia (AAD) patients in Canada
- 18 April 2026
- Published by Elsevier in International Psychogeriatrics
- Vol. 38 (5) , 100209
Open AccessTreatment patterns of agitation associated with Alzheimer’s dementia (AAD) patients in Canada
- Open Access
- 7 June 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (25) , 1741-1752
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis
Aim: To examine whether tumor-specific and tumor-agnostic oncology trials produce comparable estimates of objective response rate (ORR) in BRAF-altered cancers. Materials & methods: Electronic data... Plain language summary Two types of studies were sought, including studies that measured health outcomes in patients who were selected to receive medicine based on the location of their cancer (tum... Tweetable abstract For BRAF-altered advanced cancers, tumor-agnostic clinical trials do not yield substantially different results from tumor-specific studies and may offer a more efficient method f...
- 7 June 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (25) , 1741-1752
Open AccessComparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis
Aim: To examine whether tumor-specific and tumor-agnostic oncology trials produce comparable estimates of objective response rate (ORR) in BRAF-altered cancers. Materials & methods: Electronic data... Plain language summary Two types of studies were sought, including studies that measured health outcomes in patients who were selected to receive medicine based on the location of their cancer (tum... Tweetable abstract For BRAF-altered advanced cancers, tumor-agnostic clinical trials do not yield substantially different results from tumor-specific studies and may offer a more efficient method f...
- 14 July 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 21 (7) , 1955-1956
Revisiting Triggers: Optimal Thresholds for Transfusion in Gastrointestinal Bleeding May Be Higher Than Restrictive Guidelines
- 14 July 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 21 (7) , 1955-1956
Revisiting Triggers: Optimal Thresholds for Transfusion in Gastrointestinal Bleeding May Be Higher Than Restrictive Guidelines
- 18 November 2021
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 67 (3) , 226-234
Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study
Objective: The objective of this study was to analyze the real-world prevalence of long-acting injectable (LAI) antipsychotic use and determine when LAIs are being used in sequencing of antipsychotic medications among Canadian patients with schizophrenia. Methods: This was a retrospective, longitudinal cohort study using Canadian pharmacy prescription data between August 2005 and June 2017. Patients with inferred schizophrenia spectrum disorder were indexed on the date of their first antipsychotic prescription and analyzed for minimum 12 months to track lines of antipsychotic therapy and LAI utilization. Results: A total of 16,300 patients were identified for analysis. 48.2% and 46.0% of index antipsychotic prescriptions were prescribed by a general practitioner/family medicine doctor and psychiatrist, respectively. 1,062 (6.5%) patients used an LAI during the study period. Of those patients, 789 used an LAI within two years of index (74.3% of LAI users; 4.8% of all patients). The majority of LAI use (62.0%) occurred in the third line of therapy or later. 65.0% of patients had tried at least two therapy lines, and most patients reported gaps of six months to one year between treatment lines. Conclusion: Despite their potential to reduce relapse in schizophrenia by improving treatment adherence, this study shows LAIs continue to be under-utilized in Canada. When used, LAIs are positioned late in sequencing of antipsychotic medications, often not initiated until years after diagnosis. Continued preference for oral APs with poor adherence may be negatively impacting prognosis and exacerbating burden of schizophrenia. Efforts should be invested to understand barriers to LAI uptake and advocate for earlier, widespread use of LAIs.
- 18 November 2021
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 67 (3) , 226-234
Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study
Objective: The objective of this study was to analyze the real-world prevalence of long-acting injectable (LAI) antipsychotic use and determine when LAIs are being used in sequencing of antipsychotic medications among Canadian patients with schizophrenia. Methods: This was a retrospective, longitudinal cohort study using Canadian pharmacy prescription data between August 2005 and June 2017. Patients with inferred schizophrenia spectrum disorder were indexed on the date of their first antipsychotic prescription and analyzed for minimum 12 months to track lines of antipsychotic therapy and LAI utilization. Results: A total of 16,300 patients were identified for analysis. 48.2% and 46.0% of index antipsychotic prescriptions were prescribed by a general practitioner/family medicine doctor and psychiatrist, respectively. 1,062 (6.5%) patients used an LAI during the study period. Of those patients, 789 used an LAI within two years of index (74.3% of LAI users; 4.8% of all patients). The majority of LAI use (62.0%) occurred in the third line of therapy or later. 65.0% of patients had tried at least two therapy lines, and most patients reported gaps of six months to one year between treatment lines. Conclusion: Despite their potential to reduce relapse in schizophrenia by improving treatment adherence, this study shows LAIs continue to be under-utilized in Canada. When used, LAIs are positioned late in sequencing of antipsychotic medications, often not initiated until years after diagnosis. Continued preference for oral APs with poor adherence may be negatively impacting prognosis and exacerbating burden of schizophrenia. Efforts should be invested to understand barriers to LAI uptake and advocate for earlier, widespread use of LAIs.